Last reviewed · How we verify
Short Chain Fatty Acid
At a glance
| Generic name | Short Chain Fatty Acid |
|---|---|
| Also known as | Sodium butyrate and sodium propionate |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Metabolic Effects of Short-Chain Fatty Acids in Healthy Individuals (NA)
- Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults (NA)
- Assessment of the Effects of Probiotic Supplementation on Gut Microbiota Composition and Short-chain Fatty Acid Production in Frail Elderly Patients Receiving Home Enteral Nutrition With an Oligomeric Formula. (NA)
- Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients (NA)
- The Impact of Short-Chain Fatty Acids on Gut Hormone Release After Delivery in the Small and Large Intestine of Healthy Volunteers (NA)
- The Systemic Concentration of Short-Chain Fatty Acids After Delivery in the Small and Large Intestine of Healthy Volunteers (NA)
- Fecal Microbiota And Metabolites In Head And Neck Cancer Patients Receiving (Chemo)Radiotherapy (NA)
- Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short Chain Fatty Acid CI brief — competitive landscape report
- Short Chain Fatty Acid updates RSS · CI watch RSS
- UNC Lineberger Comprehensive Cancer Center portfolio CI